In Cancer, the Antibody Beat Goes On

For the second time since the summer, a Top-Ten pharma company with an established oncology franchise has enlisted the aid of a biotech to give it a leg up in the development and manufacturing of therapeutic antibodies. In July, it was Aventis. Now, AstraZeneca is teaming up with human antibody producer Abgenix.

For the second time since the summer, a Top-Ten pharma company with an established oncology franchise has enlisted the aid of a biotech to give it a leg up in the development and manufacturing of therapeutic antibodies. In July, Aventis SA announced its foray into the field, via a deal with ImmunoGen Inc. [See Deal](See "Aventis Antes Up in Antibodies," IN VIVO, Sept. 2003 Also see "Aventis Antes Up in Antibodies " - In Vivo, 1 September, 2003..) Now, AstraZeneca PLC is teaming up with human antibody producer Abgenix Inc. in a transaction of much larger scope. [See Deal]

Like Aventis, AstraZeneca over the past two years had done a strategic review of its oncology program and decided it...

More from Manufacturing Focus

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.